Comparison of cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed/refractory multiple myeloma
Background In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) …
ME Agha, AD Cohen, D Madduri, YC Cohen… - 2021 - ascopubs.org
8013 Background: Cilta-cel is a CAR T-cell therapy expressing two BCMA-targeting, single-
domain antibodies designed to confer avidity. The multicohort, phase 2 CARTITUDE-2 study …
domain antibodies designed to confer avidity. The multicohort, phase 2 CARTITUDE-2 study …
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple …
NWCJ van de Donk, ME Agha, AD Cohen, YC Cohen… - 2022 - ascopubs.org
8029 Background: In cohort B of the multicohort phase 2 CARTITUDE-2 (NCT04133636)
study, the efficacy and safety of cilta-cel are being evaluated in patients (pts) with MM who …
study, the efficacy and safety of cilta-cel are being evaluated in patients (pts) with MM who …
Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R …
SZ Usmani, JG Berdeja, D Madduri, AJ Jakubowiak… - 2021 - ascopubs.org
8005 Background: CARTITUDE-1 (NCT03548207) is a phase 1b/2 study evaluating
ciltacabtagene autoleucel (cilta-cel; JNJ-68284528), a CAR T-cell therapy with two BCMA …
ciltacabtagene autoleucel (cilta-cel; JNJ-68284528), a CAR T-cell therapy with two BCMA …
Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year …
T Martin, SZ Usmani, JG Berdeja, M Agha… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of
ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory …
ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory …
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma …
JG Berdeja, D Madduri, SZ Usmani, A Jakubowiak… - The Lancet, 2021 - thelancet.com
Background CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene
autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation …
autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation …
Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years …
SZ Usmani, TG Martin, JG Berdeja, AJ Jakubowiak… - 2022 - ascopubs.org
8028 Background: Ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T (CAR-
T) cell therapy with 2 B-cell maturation antigen (BCMA)–targeting single-domain antibodies …
T) cell therapy with 2 B-cell maturation antigen (BCMA)–targeting single-domain antibodies …
[HTML][HTML] CARTITUDE-2: efficacy and safety of ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy, in …
NWCJ Van de Donk, M Delforge, M Agha, AD Cohen… - Blood, 2021 - Elsevier
Introduction: Patients (pts) with multiple myeloma (MM) who experience early clinical
relapse, defined as disease progression≤ 12 mo after autologous stem cell transplantation …
relapse, defined as disease progression≤ 12 mo after autologous stem cell transplantation …
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry …
T Martin, A Krishnan, K Yong, K Weisel, M Mehra… - …, 2022 - Wiley Online Library
Introduction Ciltacabtagene autoleucel (cilta‐cel) is a novel chimeric antigen receptor T‐cell
therapy that is being evaluated in the CARTITUDE‐1 trial (NCT03548207) in patients with …
therapy that is being evaluated in the CARTITUDE‐1 trial (NCT03548207) in patients with …
[HTML][HTML] Updated results from CARTITUDE-1: phase 1b/2Study of ciltacabtagene autoleucel, a b-cell maturation antigen-directed chimeric antigen receptor T cell …
T Martin, SZ Usmani, JG Berdeja, A Jakubowiak… - Blood, 2021 - Elsevier
Introduction: Ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T (CAR-T) cell
therapy with 2 B-cell maturation antigen (BCMA) targeting single-domain antibodies …
therapy with 2 B-cell maturation antigen (BCMA) targeting single-domain antibodies …